Zeptometrix™ Corporation (ZMC) Releases HIV 1/2 Verification Panel to Support Quality Assurance Compliance with the CDC Recommendations for Laboratory Testing for HIV Infection

Newswise — Buffalo, NY - ZeptoMetrix™ Corporation (ZMC), an industry leader and innovator of quality and reliable products and services for infectious disease diagnostic development, is pleased to announce the release of a low cost HIV Verification Panel (KZMC029 HIV 1/2 Rapid Test Verification Panel). This Panel is intended to be used in support of the FDA’s only approved assay on today’s market for HIV antibody differentiation purposes – Bio-Rad’s Multispot HIV-1/HIV-2 Rapid Test.

The ZeptoMetrix™ KZMC029 HIV 1/2 Rapid Test Verification Panel has been specifically designed for laboratory training and ongoing Quality Assurance when assessing HIV antibody differentiation for HIV-1 and HIV-2 infections in repeatedly reactive samples run on 4th generation HIV platforms.

KZMC029 consists of HIV patient samples representing all possible HIV antibody reactivities for both differentiated and undifferentiated samples as described in Bio-Rad’s Multispot HIV-1/HIV-2 Rapid Test Package Insert. The ZeptoMetrix™ HIV 1/2 Rapid Test Verification Panel contains ten (10) safe to use inactivated specimens from HIV-1 and HIV-2 donors at various antibody reactivities.

Due to the significance of this Panel, ZeptoMetrix™ is offering a significantly reduced price point to better assist laboratories to minimize expenses and thereby maximize the frequency of necessary technical training.

Fisher HealthCare is the domestic distributor of ZeptoMetrix™ finished products. To order the KZMC029 HIV 1/2 Rapid Test Verification Panel or any other ZeptoMetrix™ Products, please contact your Fisher HealthCare Representative at 800-640-0640 or visit the Fisher HealthCare website (Catalog #22-157-821). For more information, please contact:

Michael Hershfield, Director, Sales & Marketing ZeptoMetrix™ Corporation 508-553-5852 [email protected]